{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:12:37Z","timestamp":1788459157659,"version":"build-2803163510"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Non-alcoholic steatohepatitis (NASH) is the progressive stage of non-alcoholic fatty liver disease (NAFLD). The non-absorbable antibiotic rifaximin has been used for treatment of irritable bowel syndrome, traveling diarrhea, and hepatic encephalopathy, but the efficacy of rifaximin in NASH patients remains controversial. This study investigated the effects and underlying mechanisms of rifaximin treatment in mice with methionine and choline deficient (MCD) diet-induced NASH. We found that rifaximin greatly ameliorated hepatic steatosis, lobular inflammation, and fibrogenesis in MCD-fed mice. Bacterial 16S rRNA sequencing revealed that the gut microbiome was significantly altered in MCD-fed mice. Rifaximin treatment enriched 13 amplicon sequence variants (ASVs) belonging to the groups <jats:italic>Muribaculaceae<\/jats:italic>, <jats:italic>Parabacteroides<\/jats:italic>, <jats:italic>Coriobacteriaceae_UCG-002<\/jats:italic>, <jats:italic>uncultured Oscillospiraceae<\/jats:italic>, <jats:italic>Dubosiella<\/jats:italic>, <jats:italic>Rikenellaceae_RC9_gut_group<\/jats:italic>, <jats:italic>Mucispirillum<\/jats:italic>, and <jats:italic>uncultured Desulfovibrionaceae<\/jats:italic>. However, rifaximin treatment also reduced seven ASVs in the groups <jats:italic>Aerococcus<\/jats:italic>, <jats:italic>Oscillospiraceae<\/jats:italic>, <jats:italic>uncultured Ruminococcaceae<\/jats:italic>, <jats:italic>Bilophila<\/jats:italic>, <jats:italic>Muribaculaceae<\/jats:italic>, <jats:italic>Helicobacter<\/jats:italic>, and <jats:italic>Alistipes<\/jats:italic> in MCD-fed mice. Bile acid-targeted metabolomic analysis indicated that the MCD diet resulted in accumulation of primary bile acids and deoxycholic acid (DCA) in the ileum. Rifaximin delivery reduced DCA levels in MCD-fed mice. Correlation analysis further showed that DCA levels were associated with differentially abundant ASVs modulated by rifaximin. In conclusion, rifaximin may ameliorate NASH by decreasing ileal DCA through alteration of the gut microbiome in MCD-fed mice. Rifaximin treatment may therefore be a promising approach for NASH therapy in humans.<\/jats:p>","DOI":"10.3389\/fphar.2022.841132","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T11:24:42Z","timestamp":1649071482000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids"],"prefix":"10.3389","volume":"13","author":[{"given":"Jie","family":"Jian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Tong","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoyu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Fen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/MEG.0000000000001232","article-title":"Rifaximin in Nonalcoholic Fatty Liver Disease: Hit Multiple Targets with a Single Shot","volume":"30","author":"Abdel-Razik","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile Acids and Nonalcoholic Fatty Liver Disease: Molecular Insights and Therapeutic Perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin Treatment in Hepatic Encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.jhep.2021.08.004","article-title":"Microbiome Therapeutics for Hepatic Encephalopathy","volume":"75","author":"Bloom","year":"2021","journal-title":"J. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/hep.31708","article-title":"The Use of Rifaximin in Patients with Cirrhosis","volume":"74","author":"Caraceni","year":"2021","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/toxsci\/kfs211","article-title":"Chronic Exposure to Rifaximin Causes Hepatic Steatosis in Pregnane X Receptor-Humanized Mice","volume":"129","author":"Cheng","year":"2012","journal-title":"Toxicol. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/hepr.12904","article-title":"Rifaximin in Non-alcoholic Steatohepatitis: An Open-Label Pilot Study","volume":"48","author":"Cobbold","year":"2018","journal-title":"Hepatol. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","article-title":"Pleiotropic Roles of Bile Acids in Metabolism","volume":"17","author":"de Aguiar Vallim","year":"2013","journal-title":"Cell Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1517\/14656566.2011.546347","article-title":"Biologic Properties and Clinical Uses of Rifaximin","volume":"12","author":"DuPont","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/164_2019_227","article-title":"Obeticholic Acid: An Update of its Pharmacological Activities in Liver Disorders","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb Exp. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"101094","DOI":"10.1016\/j.plipres.2021.101094","article-title":"Bile Acids and Their Receptors in Metabolic Disorders","volume":"82","author":"Fiorucci","year":"2021","journal-title":"Prog. Lipid Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic Steatohepatitis: the Role of Peroxisome Proliferator-Activated Receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1002\/hep.32024","article-title":"Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator\u2010Activated Receptor Story Goes on!","volume":"74","author":"Francque","year":"2021","journal-title":"Hepatology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD Development and Therapeutic Strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.3390\/ijms21155589","article-title":"Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis","volume":"21","author":"Fujinaga","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/MEG.0000000000000348","article-title":"Efficacy of Rifaximin on Circulating Endotoxins and Cytokines in Patients with Nonalcoholic Fatty Liver Disease","volume":"27","author":"Gangarapu","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1055\/s-0041-1723752","article-title":"Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers","volume":"41","author":"Gil-G\u00f3mez","year":"2021","journal-title":"Semin. Liver Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-physiol-021115-105331","article-title":"Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease","volume":"78","author":"Haas","year":"2016","journal-title":"Annu. Rev. Physiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00535-019-01649-8","article-title":"Intestinal Microbiome and NAFLD: Molecular Insights and Therapeutic Perspectives","volume":"55","author":"Hu","year":"2020","journal-title":"J. Gastroenterol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"664177","DOI":"10.3389\/fphar.2021.664177","article-title":"The Nonsteroidal Anti-inflammatory Drug Ketorolac Alters the Small Intestinal Microbiota and Bile Acids without Inducing Intestinal Damage or Delaying Peristalsis in the Rat","volume":"12","author":"Hutka","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"D480","DOI":"10.1093\/nar\/gkm882","article-title":"KEGG for Linking Genomes to Life and the Environment","volume":"36","author":"Kanehisa","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1111\/1750-3841.15929","article-title":"Heukcha, Naturally post\u2010fermented green tea Extract, Ameliorates Diet\u2010induced Hypercholesterolemia and NAFLD in Hamster","volume":"86","author":"Kang","year":"2021","journal-title":"J. Food Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cld.2017.08.010","article-title":"Nonalcoholic Fatty Liver Disease and Metabolic Syndrome","volume":"22","author":"Kim","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1099\/00207713-51-1-39","article-title":"Clostridium Hiranonis Sp. nov., a Human Intestinal Bacterium with Bile Acid 7alpha-Dehydroxylating Activity","volume":"51","author":"Kitahara","year":"2001","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nbt.2676","article-title":"Predictive Functional Profiling of Microbial Communities Using 16S rRNA Marker Gene Sequences","volume":"31","author":"Langille","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.livres.2018.12.001","article-title":"Hepatic Lipid Homeostasis by Peroxisome Proliferator-Activated Receptor Gamma 2","volume":"2","author":"Lee","year":"2018","journal-title":"Liver Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.apsb.2019.07.003","article-title":"Targeted Delivery of Hyaluronic Acid Nanomicelles to Hepatic Stellate Cells in Hepatic Fibrosis Rats","volume":"10","author":"Li","year":"2020","journal-title":"Acta Pharm. Sin B"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1002\/1873-3468.13879","article-title":"SHP-1 Ameliorates Nonalcoholic Steatohepatitis by Inhibiting Proinflammatory Cytokine Production","volume":"594","author":"Lin","year":"2020","journal-title":"FEBS Lett."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a Nuclear Receptor for Bile Acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/1873-3468.12689","article-title":"Deletion of HNF1\u03b1 in Hepatocytes Results in Fatty Liver-Related Hepatocellular Carcinoma in Mice","volume":"591","author":"Ni","year":"2017","journal-title":"FEBS Lett."},{"key":"B31","doi-asserted-by":"publisher","first-page":"20157","DOI":"10.1038\/srep20157","article-title":"Involvement of Resistin-like Molecule \u03b2 in the Development of Methionine-Choline Deficient Diet-Induced Non-alcoholic Steatohepatitis in Mice","volume":"6","author":"Okubo","year":"2016","journal-title":"Sci. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3390\/biology10100948","article-title":"Neuron-Derived Extracellular Vesicles Modulate Microglia Activation and Function","volume":"10","author":"Peng","year":"2021","journal-title":"Biology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3920\/BM2019.0171","article-title":"Increased Faecalibacterium Abundance Is Associated with Clinical Improvement in Patients Receiving Rifaximin Treatment","volume":"11","author":"Ponziani","year":"2020","journal-title":"Benef Microbes"},{"key":"B35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/cld.81","article-title":"Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup","volume":"1","author":"Puri","year":"2012","journal-title":"Clin. Liver Dis. (Hoboken)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/cr.2015.84","article-title":"An HNF1\u03b1-Regulated Feedback Circuit Modulates Hepatic Fibrogenesis via the Crosstalk between Hepatocytes and Hepatic Stellate Cells","volume":"25","author":"Qian","year":"2015","journal-title":"Cell Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"D590","DOI":"10.1093\/nar\/gks1219","article-title":"The SILVA Ribosomal RNA Gene Database Project: Improved Data Processing and Web-Based Tools","volume":"41","author":"Quast","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"357ra122","DOI":"10.1126\/scitranslmed.aaf4823","article-title":"Inhibition of Ileal Bile Acid Uptake Protects against Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Mice","volume":"8","author":"Rao","year":"2016","journal-title":"Sci. Transl Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/nu13020394","article-title":"Chronic Oleoylethanolamide Treatment Decreases Hepatic Triacylglycerol Level in Rat Liver by a PPAR\u03b3\/SREBP-Mediated Suppression of Fatty Acid and Triacylglycerol Synthesis","volume":"13","author":"Romano","year":"2021","journal-title":"Nutrients"},{"key":"B40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-Beta-Muricholic Acid, a Naturally Occurring FXR Antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cel Metab"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut Microbiota and Intestinal FXR Mediate the Clinical Benefits of Metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal Crosstalk between Bile Acids and Microbiota and its Impact on Host Metabolism","volume":"24","author":"Wahlstr\u00f6m","year":"2016","journal-title":"Cel Metab"},{"key":"B43","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.gastro.2013.10.026","article-title":"Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats","volume":"146","author":"Xu","year":"2014","journal-title":"Gastroenterology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.lfs.2017.11.027","article-title":"Baicalin Attenuates Non-alcoholic Steatohepatitis by Suppressing Key Regulators of Lipid Metabolism, Inflammation and Fibrosis in Mice","volume":"192","author":"Zhang","year":"2018","journal-title":"Life Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary Cholesterol Drives Fatty Liver-Associated Liver Cancer by Modulating Gut Microbiota and Metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"key":"B47","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bbalip.2019.02.003","article-title":"iPla2\u03b2 Deficiency in Mice Fed with MCD Diet Does Not Correct the Defect of Phospholipid Remodeling but Attenuates Hepatocellular Injury via an Inhibition of Lipid Uptake Genes","volume":"1864","author":"Zhu","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cel Biol Lipids"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.841132\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T15:29:11Z","timestamp":1649172551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.841132\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":47,"alternative-id":["10.3389\/fphar.2022.841132"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.841132","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"article-number":"841132"}}